Liquidity and Capital Resources	6 Months Ended
Jun. 30, 2016
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	11. Liquidity and Capital Resources At June 30, 2016, the Company had cash and cash equivalents of approximately $55.9 million. On July 20, 2016, we completed a public offering of common shares and one-year warrants for net proceeds of approximately $18.3 million. Management believes that our current cash and cash equivalents, along with the net proceeds of the public offering (See Note 15), will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2016 and the first six months of 2016 of approximately $42.7 million, which includes approximately $21.6 million for our clinical programs for aldoxorubicin, approximately $5.3 million for the development of our new drug candidate, DK049 and for the expansion of our Freiburg operations, approximately $3.2 million for general operation of our clinical programs, approximately $8.9 million for other general and administrative expenses, and approximately $3.7 million for interest and payments on the term loan. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections. If we obtain marketing approval and successfully commercializes aldoxorubicin or other product candidates, we anticipate it could take several years, for it to generate significant recurring revenue. We will be dependent on future financing and possible strategic partnerships until such time, if ever, as it can generate significant recurring revenue. We have no commitments from third parties to provide any additional financing, and it may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs or clinical trials, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourself, or seek to sell some or all of our assets or merge with or be acquired by another company. Following our announcement of the analysis of our on-going global Phase 3 clinical trial of aldoxorubicin, we have taken measures to reduce our burn rate and decreased our head count , and have stopped our pre-commercialization activities for the present time.

11. Liquidity and Capital Resources

At June 30, 2016, the Company had cash and cash equivalents of approximately $55.9 million. On July 20, 2016, we completed a public offering of common shares and one-year warrants for net proceeds of approximately $18.3 million. Management believes that our current cash and cash equivalents, along with the net proceeds of the public offering (See Note 15), will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2016 and the first six months of 2016 of approximately $42.7 million, which includes approximately $21.6 million for our clinical programs for aldoxorubicin, approximately $5.3 million for the development of our new drug candidate, DK049 and for the expansion of our Freiburg operations, approximately $3.2 million for general operation of our clinical programs, approximately $8.9 million for other general and administrative expenses, and approximately $3.7 million for interest and payments on the term loan. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.

If we obtain marketing approval and successfully commercializes aldoxorubicin or other product candidates, we anticipate it could take several years, for it to generate significant recurring revenue. We will be dependent on future financing and possible strategic partnerships until such time, if ever, as it can generate significant recurring revenue. We have no commitments from third parties to provide any additional financing, and it may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs or clinical trials, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourself, or seek to sell some or all of our assets or merge with or be acquired by another company. Following our announcement of the analysis of our on-going global Phase 3 clinical trial of aldoxorubicin, we have taken measures to reduce our burn rate and decreased our head count , and have stopped our pre-commercialization activities for the present time.